with urease. A third minor metabolite was present in urine collected after intraperitoneal administration but remains unidentified. The quantitative distribution of pterin-dcarboxylic acid and urea in the 0-24 h urine samples is shown in Table 1 . Fukushima & Nixon (1980) reported the degradation of [2-14C]pterin-6-carboxylic acid to 14C02 by the gut microorganisms of the rat. It is possible that this has occurred in vivo in these experiments and the resulting 14C0, lost. Thus it appears that the pterin ring is not stable in vivo as pterin-6-carboxylic acid is metabolized to urea and possibly CO, in the rat. The contribution of the gut microflora to this process remains to be established.
Labelled urea and 14C0, are detected as metabolites after the administration of [ 2-l4Clfolates to rats and guinea pigs (Connor et al., 1977; Connor & Blair, 1979; R. Choolun, personal communication) . The results reported here suggest that pterin-6-carboxylic acid may be an intermediate in the formation of these catabolites from folate. However, pterin-6-carboxylic acid is excreted at least partly unchanged and the absence of pterin-6-carboxylic acid from the urine of rats given folate suggests the oxidative breakdown of dihydropteroyl-L-glutamate is a minor route of metabolism under normal circumstances. Rats treated with methotrexate excrete pterin-6-carboxylic acid as a catabolite of folate polyglutamates (A. Saleh, unpublished work) . In these rats the inhibition of dihydrofolate reductase causes a build-up of dihydropteroyl-L-glutamate derivatives and leads to increased folate breakdown. Snake a-toxins are now well established as high-affinity specific antagonists of nicotinic acetylcholine receptors in mammalian muscle and on electroplax cells (Lee, 1979) . Such toxins have also been used as probes for nicotinic acetylcholine receptors in vertebrate central nervous system. Here, however, the relationship is less clear, and, although binding of a-toxins to material prepared from vertebrate brain has been reported, only in the case of the chick optic tectum has it so far proved possible clearly to demonstrate the blockade by a-toxin of a physiological response to acetylcholine (Barnard et al., 1979) . In view of these facts and of other suggestions of pharmacological differences between nicotinic acetylcholine receptors of peripheral and central nervous systems (Schmidt et al., 1980) , we decided to investigate the use of alternative probes for such receptors of mammalian central nervous system. We have recently been able to show limited but significant binding of anti-(rat muscle nicotinic acetylcholine receptor) antibodies to a-bungarotoxin-binding protein from rat brain (Wonnacott et al., 1980, and unpublished work) , and it was decided to examine the possible effects of such antibodies on cholinergic function in the same tissue. In this respect the presynaptic cholinergic modulation of dopamine (2,4-dihydroxyphenethylamine) release from striatal nerve terminals (de Belleroche & Bradford, 1978; Giorguieff et al., 1977) appeared to provide a suitable target.
Male Wistar rats were decapitated and striata were quickly dissected out and homogenized in incubation medium (30vol.) containing 125 mM-NaC1, 25 mM-NaHCO,, 3 mM-KCI, 0.5 mM-KH,PO,, 2mM-CaC1,, 1 mM-MgCI,, 10mM-ghcose and 1 0~~-pargyline (N-methyl-N-2-propynyIbenzylamine), pH 7.4. The homogenate ( l m g of protein/ml) was incubated at 37OC for 30min with {W}dopamine ( 5 0 n~; 47Ci/mmol), and the loaded dopaminergic terminals were than separated by centrifugation, well washed and resuspended in incubation medium. The subsequent release of radiolabelled dopamine into the medium was determined by centrifugation after incubation of the preparation at 37OC for 15min in the presence or absence of various test substances; potential inhibitors of evoked release were added lOmin earlier.
Addition of acetylcholine to the medium (in the presence of 100pM-eserine to inhibit acetylcholinesterase) increased the resting efAux of radiolabelled dopamine. This stimulation increased with increasing concentrations of acetylcholine up to a maximum of 60% at 100pM-acetylcholine: higher concentrations gave no further increase in release. The effect of anti-(rat muscle nicotinic acetylcholine receptor) antibodies on the release of dopamine evoked by 100pM-acetykholine is shown in Fig. 1 . Increasing concentrations of rabbit anti-(rat muscle nicotinic acetylcholine receptor) immunoglobulin G showed progressive inhibition of acetylcholine-evoked dopamine release up to an apparently maximal inhibition of 50% at 0.13 mg of immunoglobulin G protein/ml of brain suspension. Control immunoglobulin G obtained from normal rabbits showed no significant inhibition of evoked release. Similar effects were shown by corresponding unfractionated antisera (Fig. 1) . These results suggest the presence of an acetylcholine receptor on dobaminergic nerve terminals that is immunologically related to peripheral-nerve nicotinic acetylcholine receptors. The pharmacology of the system is, however, far from clear, in that acetylcholine-evoked release of 13H1dopamine is not significantly inhibited by a-bungarotoxin at concentrations less than O.I,UM, whereas at higher concentrations the toxin alone actually stimulated [ 3H1dopamine release, a conclusion that may also be drawn from the data of de Belleroche & Bradford (1978) .
The effects of anti-(muscle acetylcholine receptor) antibodies on brain synaptic transmission are particularly relevant to the autoimmune disease myasthenia gravis, in which such antibodies can occur in cerebrospinal fluid (Lefvert & Pirskanen, 1977) and with which central dysfunctions have been associated (Hokkanen & Toivakka, 1969) .
